2007
GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS PREDICTION BY USING PROTEOMIC APPROACHES
KAPLANOVÁ, Alexandra, Zbyněk ZDRÁHAL, Hana KONEČNÁ, Ondrej ŠEDO, Jiří MAYER et. al.Základní údaje
Originální název
GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS PREDICTION BY USING PROTEOMIC APPROACHES
Název česky
REAKCE ŠTĚPU PROTI HOSTITELI PO ALOGENNÍ TRANSPLANTACI KMENOVÝCH BUNĚK A JEJÍ PREDIKCE POMOCÍ PROTEOMICKÝCH PŘÍSTUPŮ
Autoři
Vydání
XI. Setkání biochemiků a molekulárních biologů, 2007
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
Genetika a molekulární biologie
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Organizační jednotka
Lékařská fakulta
ISBN
978-80-210-4234-6
Klíčová slova anglicky
acute graft-versus-host disease; proteomics; biomarkers
Změněno: 11. 4. 2011 13:33, Mgr. Ondrej Šedo, Ph.D.
V originále
Stem cell transplantation is a technique that can restore the marrow function of patients with severe injury to that side. Marrow injury can occur because of primary marrow failure, destruction of marrow by disease or intensive chemical or radiation exposure. Allogeneic stem cell transplantation (allo-SCT) which is a transplantation between two individuals and used as a curative approach to many hematopoietic malignancies successfully. Despite of its curative potential, the application of allo-SCT is limited by life-threatening complications such as severe acute graft-versus-host disease (GvHD) when the transplanted donor blood stem cells attack the patient s body, e.g. skin, gastrointestinal tract, liver, etc. Currently, diagnosis of GvHD is based mainly on evaluation of clinical symptoms such as skin rash, diarrhea, elevation of serum liver enzymes, etc. Organ biopsies are required to distinguish GvHD from other common complications with similar clinical symptoms (e.g. reactivation of endogenous viruses or medication-induced side effects). Differentially expressed or excreted polypeptides and proteins have potential for early and accurate diagnosis of GvHD and other complications of allo-SCT. Several potential GvHD biomarkers were published and further intensive studies are in progress. Proteomic approaches 2-D gel electrophoresis followed by mass spectrometric analysis were used for discovery of potential biomarkers suitable for early prediction of GvHD. Blood plasma, urine and lymphocytes were tested in this project. Differentially expressed proteins were observed in blood plasma with and without clinically diagnosed GvHD. Blood plasma samples were collected from the beginning of pre-transplantation treatment (usually 7 days before allo-SCT) up to the day 100 after allo-SCT. Based on presented data C-Reactive protein and Amyloid related serum protein SAA might be useful as GvHD markers suitable for potential disease management.
Česky
Stem cell transplantation is a technique that can restore the marrow function of patients with severe injury to that side. Marrow injury can occur because of primary marrow failure, destruction of marrow by disease or intensive chemical or radiation exposure. Allogeneic stem cell transplantation (allo-SCT) which is a transplantation between two individuals and used as a curative approach to many hematopoietic malignancies successfully. Despite of its curative potential, the application of allo-SCT is limited by life-threatening complications such as severe acute graft-versus-host disease (GvHD) when the transplanted donor blood stem cells attack the patient s body, e.g. skin, gastrointestinal tract, liver, etc. Currently, diagnosis of GvHD is based mainly on evaluation of clinical symptoms such as skin rash, diarrhea, elevation of serum liver enzymes, etc. Organ biopsies are required to distinguish GvHD from other common complications with similar clinical symptoms (e.g. reactivation of endogenous viruses or medication-induced side effects). Differentially expressed or excreted polypeptides and proteins have potential for early and accurate diagnosis of GvHD and other complications of allo-SCT. Several potential GvHD biomarkers were published and further intensive studies are in progress. Proteomic approaches 2-D gel electrophoresis followed by mass spectrometric analysis were used for discovery of potential biomarkers suitable for early prediction of GvHD. Blood plasma, urine and lymphocytes were tested in this project. Differentially expressed proteins were observed in blood plasma with and without clinically diagnosed GvHD. Blood plasma samples were collected from the beginning of pre-transplantation treatment (usually 7 days before allo-SCT) up to the day 100 after allo-SCT. Based on presented data C-Reactive protein and Amyloid related serum protein SAA might be useful as GvHD markers suitable for potential disease management.
Návaznosti
| LC06034, projekt VaV |
| ||
| MSM0021622415, záměr |
|